ONDANSETRON HYDROCHLORIDE - Generic Drug Details

What are the generic sources for ondansetron hydrochloride and what is the scope of freedom to operate?

Ondansetron hydrochloride is the generic ingredient in six branded drugs marketed by Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Onesource Specialty, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Sandoz, Sun Pharm Inds (in), Teva, Wockhardt Bio Ag, Sun Pharm Inds Ltd, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Aurobindo Pharma, Pharm Assoc, Taro, Apotex, Chartwell Molecules, Chartwell Rx, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hikma Intl Pharms, Ipca Labs Ltd, and Natco Pharma Ltd, and is included in seventy-two NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for ondansetron hydrochloride. Sixty-nine suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for ONDANSETRON HYDROCHLORIDE

US Patents:	0
Tradenames:	6
Applicants:	38
NDAs:	72
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	69
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	719
What excipients (inactive ingredients) are in ONDANSETRON HYDROCHLORIDE?	ONDANSETRON HYDROCHLORIDE excipients list
DailyMed Link:	ONDANSETRON HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ONDANSETRON HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
University of Belgrade	NA
University of Rochester	PHASE2

See all ONDANSETRON HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for ONDANSETRON HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 2MG BASE/ML	INJECTABLE;INJECTION
		EQ 2MG BASE/ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ONDANSETRON HYDROCHLORIDE

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ONDANSETRON HYDROCHLORIDE

A04AA	Serotonin (5HT3) antagonists
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for ONDANSETRON HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOFRAN	Oral Solution	ondansetron hydrochloride	4 mg/5 mL	020605	1	2004-12-20

US Patents and Regulatory Information for ONDANSETRON HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	TABLET;ORAL	076252-001	Jun 25, 2007		DISCN	No	No
Hospira	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	076696-001	Dec 26, 2006		DISCN	No	No
Hikma	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	SOLUTION;ORAL	076960-001	Dec 26, 2006	AA	RX	No	Yes
Sun Pharm Inds (in)	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	TABLET;ORAL	077050-001	Jun 25, 2007		DISCN	No	No
Rising	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	TABLET;ORAL	076930-001	Jun 25, 2007		DISCN	No	No

Expired US Patents for ONDANSETRON HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-001	Dec 31, 1992	5,344,658*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-003	Aug 27, 1999	4,753,789*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	SOLUTION;ORAL	020605-001	Jan 24, 1997	5,578,628*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	INJECTABLE;INJECTION	020007-001	Jan 4, 1991	4,695,578*PED
Sandoz	ZOFRAN	ondansetron hydrochloride	SOLUTION;ORAL	020605-001	Jan 24, 1997	4,695,578*PED

Market Dynamics and Financial Trajectory for Ondansetron Hydrochloride

Last updated: January 25, 2026

Executive Summary

Ondansetron Hydrochloride, a selective 5-HT3 receptor antagonist primarily used for preventing chemotherapy-induced nausea and vomiting (CINV), has maintained a stable market presence over the past decade. With an estimated global valuation of USD 1.6 billion in 2022, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.2% until 2030. This report examines the key market drivers, competitive landscape, regulatory considerations, and financial outlooks influencing the trajectory of Ondansetron Hydrochloride.

---

What Are the Market Drivers for Ondansetron Hydrochloride?

1. Rising Incidence of Cancer and Chemotherapy Usage

• The global cancer burden is projected to reach 28.4 million cases by 2040, with rising chemotherapy treatments fueling demand for antiemetics like ondansetron.
• The increasing prevalence of hematologic and solid tumors elevates the need for supportive care drugs.

2. Expand in Postoperative Nausea and Vomiting (PONV)

• PONV affects approximately 30–40% of surgical patients, expanding ondansetron use beyond oncology, notably in anesthesia protocols.

3. Market Expansion in Emerging Economies

• Growing healthcare infrastructure in Asia-Pacific, Latin America, and Africa bolsters access to antiemetic therapies.
• Economic development in these regions drives pharmaceutical uptake.

4. Patent Expiry and Generics

• The expiration of key patents since 2015 has led to a surge in generic sales, intensifying market competition and driving down prices.

5. Increased Awareness and Healthcare Spending

• Rising awareness about supportive cancer care and improved insurance coverage in developed nations support sustained demand.

---

How Does the Competitive Landscape Look?

Key Players	Market Share (2022)	Product Portfolio	Geographic Focus	Innovations
Sanofi	~35%	Original formulation, generics	Global, with focus on North America and Europe	Biosimilars, new formulations
Teva	~20%	Generics, injectables	Global	Cost-effective formulations
Mundipharma	~10%	Extended-release formulations	Europe, Asia	Fixed-dose combinations
Other Generics	~35%	Varied	Emerging markets	Price competition

Note: The market is fragmented with several regional manufacturers contributing significantly, especially in generics.

---

What Are the Regulatory and Policy Considerations?

Region	Key Policies	Impact on Market	Recent Regulatory Developments
United States	FDA approvals, generic drug policies	Facilitates market entry for generics	2021: FDA approves multiple generic ondansetron products
European Union	EMA regulations, drug pricing policies	Regulates approvals and reimbursement	2020: EMA approves new formulations to improve bioavailability
Emerging Markets	Varying regulatory stringency	Market entry barriers, price regulations	Adoption driven by WHO prequalification programs

What Are the Financial Projections and Revenue Trends?

Current Market Size and Growth Rate

• 2022 Global Market: USD 1.6 billion
• Forecast CAGR (2023-2030): 4.2% (Source: Mordor Intelligence)

Revenue Breakdown by Region (2022)

Region	Market Share	USD Billion	Growth Drivers
North America	45%	USD 720 million	High cancer treatment rates, advanced healthcare
Europe	25%	USD 400 million	Diagnostic advancements, aging population
Asia-Pacific	20%	USD 320 million	Increasing cancer incidence, expanding healthcare infrastructure
Rest of World	10%	USD 160 million	Emerging markets, generic penetration

Key Growth Factors

• Oncology and Palliative Care Expansion: Growth in chemotherapy protocols directly correlates with antiemetic demand.
• **Generic

Market Penetration**: Cost reduction due to generics enhances accessibility, especially in price-sensitive markets.

• Innovation in Formulations: Transdermal, oral dissolvable, and injectable formats catering to patient preferences.

How Do Competitive Pricing and Patent Expiry Impact Financial Trajectory?

• The patent expiration of branded formulations since 2015 has led to a price erosion of approximately 30-50% for generic drugs (Source: IQVIA).
• Price competition is intensifying, leading to increased volume sales but lower profit margins for manufacturers.
• Companies investing in biosimilars and novel delivery systems aim to capitalize on market share without patent barriers.

---

What Are the Limitations and Risks in the Forecast?

Risk Factors	Description	Potential Impact
Regulatory Hurdles	Stringent approval processes in certain jurisdictions	Delays market entry
Drug Shortages	Manufacturing disruptions	Supply chain disruptions
Price Pressures	Healthcare cost containment policies	Reduced profit margins
Market Saturation	High penetration of generics	Slowing growth rate

---

What Are the Comparative Analysis and Alternatives?

Drug	Mechanism	Indications	Market Share	Advantages	Limitations
Ondansetron Hydrochloride	5-HT3 receptor antagonist	CINV, PONV	Largest in class	Proven efficacy, safety	Patent expiry, competition from generics
Granisetron	5-HT3 antagonist	CINV	Moderate	Similar efficacy	Slightly different dosing
Palonosetron	Longer half-life 5-HT3 antagonist	CINV, prophylaxis	Niche	Twice as long duration	Higher cost

---

How Do Patent Laws and Regulatory Pathways Affect Financial Trajectory?

Jurisdiction	Patent Duration	Data Exclusivity	Implication for Revenue
United States	20 years from filing	5 years often granted	Generics enter post-expiry, reducing revenue for originator
Europe	20 years + supplementary protection certificates	10 years data exclusivity	Similar trend as US; innovation pipeline critical
Emerging Economies	Variably shorter or absent	Less strict enforcement	Increased generics presence accelerates downward pricing

---

Key Takeaways

• The global ondansetron market maintained growth despite patent expiries, driven by increasing demand in oncology and anesthesia.
• Generics dominate, comprising approximately 55-70% of market revenue, thereby exerting downward pressure on prices.
• The Asia-Pacific region exhibits the fastest growth, propelled by expanding healthcare access and rising cancer incidence.
• Innovations in drug delivery and biosimilar development may open new revenue channels.
• Regulatory environments significantly influence market entry timing and pricing strategies.

---

What Are the Frequently Asked Questions?

1. How will patent expiries affect further revenue streams for ondansetron?
Patent expirations since 2015 have led to increased generic competition, reducing prices and profit margins for branded products. Companies need to innovate with new formulations or combination therapies to sustain revenue.

2. What promising pipeline developments could influence future market dynamics?
Development of transdermal patches, orally disintegrating tablets, and combination antiemetic regimens aim to improve patient compliance and open new market segments.

3. How sensitive is the market to healthcare policy changes?
Highly sensitive; price control policies and reimbursement changes significantly impact profitability, especially in Europe and emerging markets.

4. What are the major barriers to market expansion in developing countries?
Regulatory delays, infrastructure limitations, and pricing regulations restrict rapid market penetration, despite rising demand.

5. How does clinical evidence influence market share among ondansetron competitors?
Robust clinical data supporting efficacy and safety reinforce brand loyalty and market adoption, particularly in institutional settings like hospitals.

---

References

1. Mordor Intelligence, "Ondansetron Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2030)," 2022.
2. IQVIA Institute, "The Impact of Patents on Drug Markets," 2021.
3. European Medicines Agency, "Regulatory Updates on Antiemetics," 2020.
4. FDA, "Generic Drug Approvals and Policies," 2021.

---

This analysis aims to facilitate strategic decision-making by providing a comprehensive overview of the current and projected economic landscape for Ondansetron Hydrochloride.